Hyperfine, Inc.
HYPRHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Hyperfine, Inc. (HYPR) is listed under Medical Devices. Valued at $76.8M, HYPR is a micro-cap name in its sector. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.
Market Cap
$76.8M
Beta
1.46
P/E (TTM)
—
P/E (Fwd)
-2.26
EPS (TTM)
$-0.37
EPS (Fwd)
$-0.32
ROE
-97.0%
ROA
-38.8%
Cash
$43.5M
Total Debt
$13.4M
Free CF
-$17.2M
52W Change
-43.4%
Annual Financials
Cash vs Debt
Where HYPR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, HYPR finished 32.17% below its 150-day moving average ($1.15) and 31.58% below its 200-day moving average ($1.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HYPR overbought or oversold?
At the October 20, 2026 close, HYPR's RSI(14) was 46.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $43.5M in cash and $13.4M in debt, HYPR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$17.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -97.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $6.8M (2022) to $13.6M (2025), reflecting a 99% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HYPR.